Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed...

Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed well in two Phase III trials and one safety extension study. The trials also brought on no imbalances in serious adverse events. Astrazeneca acquired the worldwide licence for naloxegol from its developer, Nektar Therapeutics (NKTR -0.1%), in 2009. (PR)